New potential first-line therapy for patients with mCR-prostate cancer and HRR-alterations
The MAGNITUDE study highlights the importance of testing for HRR gene alterations in patients with metastatic castration-resistant prostate cancer treated with niraparib, abiraterone acetate and prednisone, as first-line therapy. In this MEDtalk Dr. Kim Chi, medical oncologist, presents results from the study and gives his perspective on the treatment as first-line therapy for this group of patients.
Get access to the article
If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.